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Summary
An	abundance	of	noninvasive	scores	have	been	associated	with	fibrosis	and	hepatocel-
lular	 carcinoma	 (HCC)	development.	We	aimed	 to	compare	 the	prognostic	ability	of	
these	scores	 in	relation	to	 liver	histology	 in	chronic	hepatitis	B	 (CHB)	patients.	Liver	
biopsies	from	treatment-	naïve	CHB	patients	at	one	tertiary	care	centre	were	scored	by	
a	single	hepato-	pathologist.	Laboratory	values	at	liver	biopsy	were	used	to	calculate	the	
PAGE-	B,	REACH-	B,	GAG-	HCC,	CU-	HCC	and	FIB-	4	scores.	Any	clinical	event	was	de-
fined	as	HCC	development,	liver	failure,	transplantation	and	mortality.	HCC	and	mortal-
ity	data	were	obtained	from	national	database	registries.	Of	557	patients,	40	developed	
a	clinical	event	within	a	median	follow-	up	of	10.1	(IQR	5.7-	15.9)	years.	The	PAGE-	B	
score	predicted	any	clinical	event	(C-	statistic.86,	95%	CI:	0.80-	0.92),	HCC	development	
(C-	statistic	 .91)	and	reduced	transplant-	free	survival	 (C-	statistic	 .83)	with	good	accu-
racy,	also	when	stratified	by	ethnicity,	antiviral	therapy	after	biopsy	or	advanced	fibro-
sis.	The	C-	statistics	(95%	CI)	of	the	REACH-	B,	GAG-	HCC,	CU-	HCC	and	FIB-	4	scores	for	
any	event	were	.70	(0.59-	0.81),	.82	(0.75-	0.89),	.73	(0.63-	0.84)	and.79	(0.69-	0.89),	re-
spectively.	 The	 PAGE-	B	 event	 risk	 assessment	 improved	modestly	 when	 combined	
with	 the	 Ishak	 fibrosis	 stage	 (C-	statistic	 .87,	 95%	CI:	 0.82-	0.93).	 The	PAGE-	B	 score	
showed	the	best	performance	in	assessing	the	likelihood	of	developing	a	clinical	event	
among	a	diverse	CHB	population	over	15	years	of	follow-	up.	Additional	liver	histologi-
cal	characteristics	did	not	appear	to	provide	a	clinically	significant	improvement.
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1  | INTRODUCTION
Approximately	350	million	patients	worldwide	have	chronic	hepatitis	
B	(CHB).	Long-	term	CHB	can	lead	to	liver	cirrhosis,	decompensation,	
hepatocellular	carcinoma	(HCC)	development	and	death.	Nearly	30%	
of	 cirrhosis	 and	 53%	 of	 all	 HCC	 is	 attributable	 to	 CHB,	 and	 about	
650	000	patients	die	to	the	complications	of	CHB	each	year.1,2	Disease	
progression	may	be	halted	by	antiviral	therapy	(AVT),	and	therefore,	it	
is	important	to	assess	the	risk	of	deterioration	for	individual	patients	
to	 be	 able	 to	 provide	 a	 timely	 intervention	 for	 those	 who	 benefit	
most.3-5	For	decades,	 liver	biopsy	has	been	the	gold	standard	to	as-
sess	the	severity	of	 liver	disease	and	the	patients’	related	prognosis.	
Abbreviations:	CHB,	chronic	hepatitis	B;	HAI,	hepatic	activity	 index;	HBeAg,	hepatitis	B	e	
antigen;	HBV,	hepatitis	B	virus;	NASH,	nonalcoholic	steatohepatitis.
Janssen	and	Hansen	are	equally	contributed.
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However,	this	procedure	is	associated	with	potentially	severe	compli-
cations,	sampling	error,	as	well	as	inter-	and	intra-	observer	variation.6,7 
Noninvasive	 objective	 surrogate	 scores	 for	 the	 long-	term	 prognosis	
are	therefore	warranted.
Recently,	 the	 FIB-	4	 and	APRI	 scores	 have	 been	 developed	 to	
estimate	the	fibrosis	severity	with	moderate	to	good	accuracy,	and	
the	FIB-	4	score	has	additionally	been	associated	with	survival	and	
HCC	development	during	5	years	of	follow-	up.8-12	Furthermore,	the	
PAGE-	B	 score	 has	 been	 developed	 to	 estimate	 the	 probability	 of	
HCC	development	in	Caucasian	CHB	patients	treated	with	entecavir	
or	tenofovir,	as	an	alternative	to	the	REACH-	B,	CU-	HCC	and	GAG-	
HCC	scores	which	were	only	associated	with	HCC	development	 in	
Asian	 patients.13-18	 It	 is	 unknown	how	 the	 prognostic	 accuracy	 of	
these	noninvasive	serum	scores	compares	to	that	of	liver	histology	
with	respect	to	the	long-	term	outcome	in	CHB	patients,	especially	
with	 regard	 to	 event-	free	 and	 transplant-	free	 survival.	 Also,	 the	
prognostic	benefit	 in	performing	a	liver	biopsy	in	addition	to	these	
noninvasive	 scores	 has,	 to	 our	 knowledge,	 not	 been	 assessed	 in	
detail.
The	 aims	 of	 the	 current	 study	 therefore	 were	 (i)	 to	 assess	 the	
prognostic	performance	of	simple	noninvasive	risk	scores	in	different	
subgroups,	and	(ii)	to	assess	whether	liver	histological	characteristics	
could	improve	this	performance	in	CHB	patients.
2  | MATERIALS AND METHODS
2.1 | Patient selection
The	 patient	 population	 and	 selection	 have	 been	 described	 previ-
ously.19	 In	short,	mono-	infected	treatment-	naïve	CHB	 (HBsAg	posi-
tive	 for	>6	months)	patients	consecutively	biopsied	 in	 the	period	of	
1985-	2012	were	 retrospectively	 identified	 in	 a	 tertiary	 care	 centre	
in	Rotterdam,	 the	Netherlands.	Patients	were	excluded	 in	case	of	a	
history	of	AVT	for	the	duration	of	>1	month	prior	to	or	at	the	time	of	
biopsy,	a	current	or	past	coinfection	with	hepatitis	C,	D,	E	or	human	
immunodeficiency	 virus,	 presence	of	 autoimmune	 liver	disease,	 pri-
mary	 biliary	 cholangitis,	Wilson’s	 disease,	 hemochromatosis	 or	 any	
other	coexisting	primary	liver	disease	or	treatment	with	immune	sup-
pressive	medication	for	more	than	6	months	prior	to	or	at	the	time	of	
biopsy.	The	study	was	conducted	in	accordance	with	the	guidelines	of	
the	Declaration	of	Helsinki	and	the	principles	of	Good	Clinical	Practice	
and	was	approved	by	the	ethical	review	board	of	the	Erasmus	Medical	
Center,	Rotterdam,	the	Netherlands.
2.2 | Data acquisition
Data	on	all-	cause	mortality	were	obtained	from	the	municipal	 re-
cord	 database,	 and	 the	 development	 of	 HCC	was	 obtained	 from	
the	national	HCC	registry	database.	The	event	of	liver	transplanta-
tion	or	decompensation	was	obtained	 from	the	 (electronic)	medi-
cal	 chart.	Data	on	demographics	 (sex,	 age,	 race,	ethnicity,	height,	
weight,	 route	 of	 hepatitis	 B	 virus	 (HBV)	 transmission,	 presumed	
date	 of	 infection)	 and	 clinical	 data	 (history,	 diagnosis	 of	 diabetes	
mellitus,	 daily	 alcohol	 intake,	 history	 of	 alcohol	 abuse,	 smoking)	
were	 obtained	 by	 a	 single	 investigator	 (WB)	 from	 the	 chart	 in	 a	
standardized	way.	Alcohol	use	was	defined	as	≥1	units	of	alcohol/
day	and	alcohol	abuse	was	defined	as	an	history	or	current	use	of	
≥5	units/day,	corresponding	to	40-	50	g	alcohol	per	day.20	Data	on	
chemistry	 (alanine	 aminotransferase	 [ALT],	 aspartate	 aminotrans-
ferase	 [AST],	 gamma-	glutyltransferase	 [y-	GT],	 bilirubin,	 albumin),	
haematology	 (platelet	 count,	 prothrombin	 time)	 and	 virology	
(HBsAg,	 anti-	HBs,	 hepatitis	 B	 e	 antigen	 [HBeAg],	 anti-	HBe,	HBV	
DNA	 load,	 HBV	 genotype)	 at	 the	 time	 of	 biopsy	 were	 obtained	
from	the	clinical	laboratory	and	the	Department	of	Virology	at	the	
Erasmus	Medical	Center.
2.3 | Liver histology
All	liver	biopsies	were	obtained	percutaneously.	These	biopsies	were	
rescored	 by	 a	 single	 experienced	 hepato-	pathologist	 (FK)	who	was	
blinded	 to	 the	 patient	 characteristics	 and	 outcome.	 Biopsies	 were	
scored	in	a	uniform	manner	according	to	the	Ishak	fibrosis	score,	the	
hepatic	activity	index	(HAI),21	the	Brunt	score	for	steatosis	and	non-
alcoholic	steatohepatitis	 (NASH),	defined	as	the	combined	presence	
of	macrovesicular	 or	microvesicular	 steatosis,	 lobular	 inflammation,	
lipogranulomas	 and	 ballooning	 degeneration.22	 Advanced	 fibrosis	
was	defined	as	an	Ishak	score	of	≥4,	corresponding	to	portal	to	portal	
bridging	 and	probable	or	 definite	 cirrhosis.	 To	minimize	 the	 chance	
of	histological	misclassification	due	to	sample	size,	liver	biopsies	with	
a	length	of	less	than	10	mm	and	with	less	than	10	portal	fields	were	
excluded	from	the	analysis.23,24
2.4 | Laboratory measurements
The	 gender	 and	 time-	dependent	 upper	 limit	 of	 normal	 values	were	
used	for	the	analysis	of	serum	ALT	and	AST.	The	HBV	DNA	level	was	
expressed	 in	 units/millilitre	 (IU/mL)	 and,	 when	 required,	 calculated	
using	the	conversion	of	1.0	pg/mL=5.15	×	104	IU/mL	or	1.0	copies/
mL=0.1818	IU/mL.	HBV	genotype	was	determined	using	the	INNO-	
LiPA	Genotype	assay	(Innogenetics,	Ghent,	Belgium)	in	case	data	on	
HBV	genotype	were	missing.
2.5 | Outcome measures
The	 occurrence	 of	 liver	 failure	 (defined	 as	 an	 episode	 of	 jaundice,	
ascites,	 hepatic	 encephalopathy	 or	 gastroduodenal	 bleeding	 due	 to	
varices),	HCC	development,	 liver	 transplantation	and	all-	cause	mor-
tality	was	studied.	We	assessed	the	occurrence	of	these	events	as	a	
composite	endpoint	(any	clinical	event)	as	well	as	separately.	In	case	
of	multiple	 events	 in	 an	 individual	 patient,	 only	 the	 first	 event	was	
considered	for	the	composite	endpoint.	The	cause	of	death	was	de-
termined	by	 the	 treating	physician.	Death	caused	by	 liver	 failure	or	
HCC	was	considered	 liver-	related.	The	diagnosis	of	HCC	was	based	
on	 histopathology	 and	when	 not	 available,	 on	 two	 imaging	modali-
ties	(magnetic	resonance	imaging,	computed	tomography	or	contrast	
enhanced	ultrasound).25
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2.6 | Statistical analysis
Baseline	was	defined	as	the	date	of	first	liver	biopsy.	Scores	for	cir-
rhosis	 and	 outcome	 were	 constructed	 as	 previously	 described	 and	
their	respective	cut-	offs	were	utilized	in	the	analysis	when	appropri-
ate	 (Table	1).	 The	 association	 between	 baseline	 clinical	 factors	 and	
(non-	)invasive	scores	and	clinical	outcome	at	long-	term	follow-	up	was	
estimated	using	 the	Cox	proportional	hazards	method.	Factors	with	
a P-	value	<.1	in	univariate	analysis	were	considered	for	multivariable	
Cox	regression	analysis.	Deceased	patients	were	censored	at	the	time	
of	 death	 for	 the	 nonmortality	 outcomes.	 Patients	who	 experienced	
liver	failure	were	considered	still	at	risk	in	the	analysis	for	HCC,	and	
vice versa.	If	there	was	no	clinical	event,	patients	were	censored	at	the	
last	follow-	up	visit.	The	C-	statistic	was	calculated	for	the	(non-	)inva-
sive	risk	scores	to	assess	the	predictive	ability	for	any	clinical	outcome	
and	risk	of	HCC.	The	risk	of	any	clinical	event	was	estimated	for	each	
individual	patient	using	the	baseline	survival	from	the	univariable	Cox	
regression	model	 using	 the	 noninvasive	 risk	 score	with	 the	 highest	
overall C-	statistic.
We	performed	additional	 analyses	 concerning	 the	net	 reclassi-
fication	improvement	(NRI)	by	adding	liver	biopsy	characteristics	to	
the	Cox	regression	model,	 in	order	to	statistically	examine	the	po-
tential	benefit	of	a	liver	biopsy.	The	C-	statistic	was	calculated	for	the	
(non-	)invasive	risk	scores	to	assess	the	predictive	ability	for	any	clin-
ical	outcome	and	risk	of	HCC.	The	risk	of	any	clinical	event	was	esti-
mated	for	each	individual	patient	using	the	hazard	function	from	the	
univariable	Cox	 regression	model	 using	 the	 noninvasive	 risk	 score	
with	 the	 highest	 overall	 C-	statistic.	 After	 addition	 of	 liver	 biopsy	
characteristics	to	the	Cox	regression	model,	we	re-	assessed	the	up-
dated	C-	statistic	and	the	updated	estimation	of	this	event	risk	using	
the	hazard	 function	of	 this	multivariable	model.	 Subsequently,	 the	
NRI	at	5	and	10	years	was	calculated,	in	order	to	obtain	the	change	
in	the	estimated	risk	and	thus	to	quantify	the	clinical	added	value	of	
a	liver	biopsy	when	combined	with	the	best	performing	noninvasive	
score.26,27
Skewed	variables	were	log-	transformed	prior	to	the	analyses.	SPSS	
version	22.0	 (SPSS	 Inc.,	Chicago,	 IL,	USA)	and	 the	SAS	9.3	program	
(SAS	 Institute	 Inc.,	 Cary,	NC,	USA)	were	 used	 to	 perform	 statistical	
analyses.	All	statistical	tests	were	two-	sided	and	evaluated	at	the	.05	
level	of	significance.
2.7 | Role of the funding source
Financial	 support	 was	 provided	 by	 the	 Foundation	 for	 Liver	 and	
Gastrointestinal	Research	 (SLO)	 in	Rotterdam,	 the	Netherlands,	 and	
by	 the	Virgo	 consortium,	 funded	by	 the	Dutch	 government	 project	
number	 FES0908,	 and	 by	 the	 NGI	 project	 number	 050-	060-	452.	
INNO-	LiPA	 assays	 were	 provided	 by	 Innogenetics	 (Belgium).	 The	
funding	sources	did	not	have	influence	on	study	design,	data	collec-
tion,	analysis	and	interpretation	of	the	data,	writing	of	the	report	or	
the	decision	to	submit	for	publication.
3  | RESULTS
3.1 | Patient characteristics
Of	880	biopsied	CHB	patients,	 163	did	not	meet	 eligibility	 criteria,	
127	were	 excluded	 because	 of	 a	missing	 chart	 or	 liver	 biopsy	 and	
33	were	excluded	because	of	an	 inadequate	 liver	biopsy	sample.	 In	
total,	557	patients	were	thus	included,	of	which	371	(67%)	were	male.	
The	mean	 age	 at	 biopsy	was	 34.7	years.	 Patient	 characteristics	 are	
presented	in	Table	2.	47%	of	patients	were	Caucasian	(n=261),	31%	
Asian	(n=175)	and	19%	African	(n=104).	HBV	genotypes	A,	B,	C,	D,	E	
and	other/mixed	were	present	in	126	(23%),	64	(12%),	98	(18%),	171	
(31%),	31	(6%)	and	8	(1%)	of	patients,	respectively.	At	baseline,	113	
(20%)	patients	had	advanced	fibrosis	and	63	(11%)	cirrhosis	(Table	1).	
Patients	who	received	AVT	after	biopsy	vs	those	who	did	not	were	
more	often	HBeAg-	positive	 (66%	vs	25%,	P<.001),	had	higher	 log10 
HBV	DNA	 load	 (6.8	 [2.2]	vs	3.9	 [2.8]	 IU/mL,	P<.001),	ALT	and	AST	
(both	P<.01),	had	 lower	thrombocyte	counts	 (P<.001)	and	had	more	
often	advanced	liver	disease	(26%	vs	12%,	P<.001).
3.2 | Events during follow- up
The	mean	duration	of	follow-	up	after	liver	biopsy	was	10.1	years	(in-
terquartile	 range	 5.7-	15.9,	maximum	27.3	years).	 Survival	 and	HCC	
status	was	available	for	515	(92.6%)	patients,	and	41	(7.2%)	patients	
emigrated	 and	were	 censored	 at	 the	 last	 follow-	up	 visit;	 follow-	up	
data	of	one	patient	(0.2%)	could	not	be	retrieved.	Fifty-	one	patients	
lost	HBsAg	(median	time	from	biopsy	3.1	years,	IQR	1.2-	8.2,	maximum	
19.2	years).	 During	 long-	term	 follow-	up,	 40	 patients	 experienced	 a	
Risk score Components Cut- offs Ref
PAGE-	B Platelets,	gender,	age <10,	10-	17,	>17 18
REACH-	B Gender,	age,	alanine	aminotransferase	(ALT),	HBeAg	
status,	hepatitis	B	virus	(HBV)	DNA	load	(copies/mL)
<8,	≥8 14
FIB-	4 Platelets,	age,	aspartate	aminotransferase	(AST),	ALT ≥3.25 9
Log	APRI Platelets,	AST >1.4 10
GAG-	HCC Gender,	age,	HBV	DNA	load	(copies/mL),	cirrhosis	(US+) <101,	≥101 15
CU-	HCC Age,	albumin,	bilirubin,	HBV	DNA	load	(copies/mL),	
cirrhosis	(US+)
<5,	≥5 13
Ultrasound+	(US+):	ultrasound	and	other	factors	indicating	cirrhosis.	In	the	current	study,	the	diagnosis	
of	cirrhosis	was	solely	based	on	liver	biopsy.
TABLE  1 Different	risk	scores	and	their	
components
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clinical	 event:	 10	 patients	 developed	 liver	 failure,	 15	 patients	were	
diagnosed	with	HCC,	seven	patients	underwent	liver	transplantation,	
and	31	patients	died.	Ten	patients	died	of	a	liver-	related	cause	(seven	
of	whom	due	to	HCC	and	three	as	a	result	of	liver	failure),	eight	died	of	
liver-	unrelated	causes	(of	which	one	patient	had	an	HCC),	and	for	13	
patients,	the	cause	of	death	was	unknown.	The	overall	5-	,	10-	and	20-	
year	event-	free	survival	was	97.6%,	94.0%	and	86.8%,	respectively.
3.3 | Factors associated with long- term 
clinical outcome
Fifty-	five	per	cent	(22/40)	of	all	patients	with	an	event	had	advanced	
fibrosis	 at	 baseline.	 The	 (non-	)invasive	 scores	were	 all	 significantly	
associated	with	the	development	of	a	clinical	event,	HCC	and	a	re-
duced	 transplant-	free	 survival	 (Table	 S1).	 In	 addition	 to	 the	 Ishak	
score	(hazard	ratio	[HR]	1.74,	95%	CI:	1.5-	2.1,	P<.001),	 liver	biopsy	
characteristics	significantly	associated	with	the	development	of	any	
clinical	event	were	the	HAI	score	(HR	1.17,	95%	CI:	1.1-	1.3,	P=.005)	
and	presence	of	steatosis	(HR	2.38,	95%	CI:	1.3-	1.4,	P=.006)	or	NASH	
(HR	2.56,	95%	CI:	1.3-	5.2,	P=.009).	Other	factors	associated	with	any	
event	were	 the	 three	 components	 of	 the	PAGE-	B	 score:	 older	 age	
(HR	per	10	years	 increase	2.3,	95%	CI:	1.8-	2.9,	P<.001),	male	 gen-
der	(HR	4.8,	95%	CI:	1.7-	13.4,	P=.003)	and	lower	thrombocyte	count	
(HR	0.85	per	10	units	increase,	95%	CI:	0.8-	0.9,	P<.001).	Moreover,	
a	higher	body	mass	index	(HR	1.1,	95%	CI:	1.0-	1.2,	P=.002),	diabetes	
mellitus	 (HR	5.7,	 95%	CI:	 2.7-	11.6,	P<.001)	 and	 alcohol	 abuse	 (HR	
4.4,	95%	CI:	1.8-	10.7,	P=.001)	were	also	associated	with	an	adverse	
clinical	outcome.
By	multivariable	 analysis,	 factors	 independently	 associated	with	
clinical	outcome	were	the	PAGE-	B	score	 (HR	1.27,	95%	CI:	1.2-	1.4,	
P<.001)	and	the	Ishak	fibrosis	stage	(HR	1.38,	95%	CI:	1.1-	1.7,	P=.003).
3.4 | Noninvasive scores vs liver biopsy for the 
prediction of clinical outcome
The	C-	statistic	for	the	PAGE-	B	score	for	the	prediction	of	any	clini-
cal	 event	was	 .86	 (95%	CI:	 0.80-	0.92,	 Table	3)	 and	was	 .83	 (95%	
CI:	0.76-	0.91)	for	reduced	transplant-	free	survival	and	.91	(95%	CI:	
0.82-	0.99)	 for	HCC	development.	The	other	noninvasive	prognos-
tic	measures	showed	a	lower	C-	statistic	for	all	respective	outcomes	
(Table	3).	When	the	Ishak	stage	was	combined	with	the	PAGE-	B,	the	
prediction	 for	 any	 clinical	 event	 improved	 (C-	statistic	 .87,	95%	CI:	
0.82-	0.93).	For	PAGE-	B	 scores	<10,	10-	17	and	>17,	 the	observed	
cumulative	 probability	 of	 any	 clinical	 event	 was	 0.9%,	 1.9%	 and	
14.2%	at	year	5,	0.9%,	3.1%	and	39.3%	at	year	10	and	2.0%,	8.7%	
and	61.2%	at	year	15,	respectively	(log-	rank	P<.001,	Figure	1).	The	
estimated	event	risk	and	HCC	risk	for	 individual	patients	using	the	
PAGE-	B	 score	 are	 shown	 in	Figure	2.	 For	 patients	with	 a	PAGE-	B	
score	 <10,	 10-	17	 and	 >17,	 the	 estimated	 5-	year	 event	 risk	 was	
<0.7%,	0.7%-	8.0%	and	≥8.0%;	the	10-	year	event	risk	<1.5%,	1.5%-	
17.5%	and	≥17.5%;	and	the	15-	year	event	risk	<3.0%,	3.0%-	32.0%	
and	≥32%,	respectively.
3.5 | Performance of noninvasive risk scores for 
clinical outcome in subgroups
For	the	prediction	of	any	clinical	event,	the	PAGE-	B	had	the	over-
all	 highest	 C-	statistic	 compared	 to	 the	 other	 noninvasive	 scores	
TABLE  2 Patient	characteristics
Characteristics All patients (N=557)
Demography
Age	at	biopsy,	years	(SD) 34.7	(12.5)
Male,	n	(%) 371	(67)
Body	mass	index	kg/m2	(SD)a 24.8	(4.1)
Diabetes,	n	(%) 29	(5)
History	of	alcohol	abuse,	n	(%)b 25	(5)
AVT	after	biopsy,	n	(%) 348	(63)
First	course/Last	course
NA	only 184	(53)
	(Peg)IFN	only 68	(19)
	(Peg)IFN/NA 84	(24)
NA/(Peg)IFN 7	(2)
Other 5	(2)
Time	(wks)	to	AVT	(IQR) NA
Ethnicity,	n	(%)
Caucasian 261	(47)
Asian 175	(31)
African/negroid 104	(19)
Other 17	(3)
Virology
HBeAg-	positive,	n	(%) 280	(50)
log	HBV	DNA,	IU/mL	(SD) 5.7	(2.8)
HBV	genotype	A/B/C/D/Ec 126/64/98/171/31
Chemistry/haematology
ALT,	×	ULN	(SD) 2.6	(3.6)
AST,	×	ULN	(SD) 1.6	(1.9)
Thrombocytes	(IQR) 206	(172-	243)
Histology,	n	(%)
Biopsy	length,	mm	(SD) 19.9	(6.8)
Portal	fields,	n	(SD) 19.9	(9.1)
Median	Ishak	fibrosis,	(IQR) 1.0	(1.0-	2.0)
Advanced	fibrosis,	n	(%) 113	(20)
Hepatic	activity	index	(SD) 4.2	(2.3)
Steatosis	(>5%),	n	(%) 179	(32)
Steatohepatitis,	n	(%) 103	(19)
Follow-	up,	years	from	biopsy	(IQR) 10.1	(5.7-	15.9)
AVT,	 antiviral	 therapy;	NA,	 nucleos(t)ide	 analogue;	 (Peg)IFN,	 (pegylated)	
interferonl	 ALT,	 alanine	 aminotransferase;	 AST,	 aspartate	 aminotrans-
ferase;	HBV,	hepatitis	B	virus;	ULN,	upper	limit	of	normal.
aAvailable	in	469	(85%)	patients.
bAvailable	in	477	(86%)	patients.
cAvailable	in	498	(90%)	patients.
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stratified	by	AVT,	advanced	fibrosis	and	ethnicity	(Table	4).	Within	
patients	with	 advanced	 fibrosis	 or	Asian	 patients,	 the	C-	statistics	
were	 comparable	 to	 the	 FIB-	4	 and	 REACH-	B,	 respectively.	 The	
C-	statistics	 obtained	with	 the	 PAGE-	B	 for	 the	 prediction	 of	HCC	
development	 in	 Asian	 patients	 who	 received	 AVT	 after	 liver	 bi-
opsy	was	 higher	 than	 the	 REACH-	B:	 this	was	 .75	 (95%	CI:	 0.53-	
0.97)	for	the	PAGE-	B	vs	.69	(95%	CI:	0.61-	0.78)	for	the	REACH-	B,	
respectively.
3.6 | Additional prognostic value of the Ishak stage 
combined with PAGE- B
The	 individual	 risk	of	 any	event	 for	patients	was	estimated	 for	 the	
combination	of	 the	PAGE-	B	with	 the	 Ishak	 fibrosis	 stage	using	 the	
hazard	function	derived	from	this	multivariable	Cox	regression	model.	
This	updated	risk	was	compared	to	the	original	estimated	risk	(hazard	
function	obtained	with	PAGE-	B	only)	vs	the	actual	observed	events	
and	nonevents	at	5-	and	10-	year	 intervals	 to	obtain	 the	NRI.	With	
the	addition	of	the	Ishak	fibrosis	stage,	two	of	12	(16.7%)	of	events	
were	 correctly	 reclassified	 into	 the	 intermediate-to-high	 risk	 group	
(PAGE-	B	score	>10,	corresponding	to	a	5-	year	event	risk	≥0.7%),	and	
three	of	430	(0.7%)	were	incorrectly	reclassified	into	the	intermedi-
ate-to-high	 risk	group	at	year	5	 (total	NRI=.160).	At	year	10,	 there	
was	no	additional	value	of	the	Ishak	score	to	classify	an	event	as	the	
PAGE-	B	alone	correctly	classified	all	24	events	into	the	intermediate-
to-high	risk	group	(10-	year	event	risk	≥1.5%).	At	year	10,	36	of	269	
(13%)	patients	were	correctly	reclassified	into	the	low-	risk	group	by	
addition	of	the	Ishak	score,	and	no	patients	were	incorrectly	reclassi-
fied	(total	NRI=.134).
Using	the	same	method,	we	also	assessed	the	NRI	for	HCC	predic-
tion.	Within	the	first	10	years	of	follow-	up,	the	PAGE-	B	score	alone	
correctly	classified	all	patients	who	developed	HCC	into	the	interme-
diate	HCC	and	high	HCC	risk	groups	(PAGE-	B	>10	corresponding	to	
an	HCC	risk	>0.2%	at	year	5	[4/4	cases]	and	>0.6%	at	year	10	[10/10	
cases])	and	no	patients	were	incorrectly	reclassified	(NRI=0).
4  | DISCUSSION
In	the	current	study,	we	have	compared	different	prognostic	scores	
for	 their	 ability	 to	 predict	 the	 clinical	 outcome	 over	 more	 than	
15	years	 of	 follow-	up	 in	CHB	patients	 of	 diverse	 ethnic	 origin	 and	
infected	with	all	major	HBV	genotypes.	We	found	that	the	PAGE-	B	
score	was	the	overall	best	performing	risk	score	to	predict	any	clinical	
outcome,	 transplant-	free	and	HCC-	free	survival	when	compared	 to	
the	REACH-	B,	FIB-	4,	APRI,	GAG-	HCC	and	CU-	HCC	risk	scores.	The	
PAGE-	B	score	also	showed	a	better	prognostic	performance	strati-
fied	by	AVT,	or	 among	 subgroups	of	 different	 ethnicity	 and	 sever-
ity	of	 liver	disease.	After	addition	of	 the	 Ishak	 fibrosis	 stage	 to	 the	
PAGE-	B	risk	score,	the	risk	assessment	obtained	by	the	PAGE-	B	risk	
score	only	modestly	improved,	which	was	further	underlined	by	the	
modest	NRI.
Since	 timely	 diagnosis	 of	 severe	 liver	 disease	 may	 improve	 pa-
tients’	 prognosis	 through	 treatment	with	 highly	 potent	AVT,	 it	 is	 of	
great	 importance	 to	 select	 those	 patients	 in	 need	 for	 intervention	
and	parallel	HCC	surveillance	by	assessing	the	risk	of	clinical	disease	
progression	 as	 early	 as	 possible.	 The	 classical	 division	 of	 CHB	 in	 a	
five-	stage	disease	continuum	has	its	limitations,	in	that	there	are	grey	
areas	in	which	there	is	doubt	whether	patients	should	or	should	not	
receive	therapy.	Therefore,	previous	research	has	provided	us	with	an	
abundance	of	 (non-	)invasive	risk	scores	to	assess	the	extent	of	 liver	
disease,	and	long-	term	outcome.	This	may	further	add	to	uncertainty	
which	score	to	use	best	 in	clinical	practice.	To	our	knowledge,	there	
have	not	been	comparisons	within	different	subgroups	between	these	
risk	scores.	Comparing	 the	different	scores	 in	 the	current	study,	we	
have	shown	that	the	PAGE-	B	score	had	the	best	overall	discriminative	
ability	to	predict	the	risk	of	any	clinical	event,	reduced	transplant-	free	
survival	and	HCC	development	over	more	than	15	years	of	follow-	up	
and	across	different	ethnicities.	Importantly,	in	the	current	cohort	we	
observed	a	better	ability	for	the	PAGE-	B	score	to	assess	the	HCC	risk	
among	 treated	Asian	 patients	 compared	 to	 the	REACH-	B.	The	vali-
dated	PAGE-	B	score	was	previously	constructed	in	a	selected	group	
Biomarker C- statistic 
(95% CI) Any event (n=40)
Transplantation or 
mortality (n=31)
HCC develop-
ment (n=15)
Noninvasive
PAGE-	B .86 (0.80-0.92) .83 (0.76-0.91) .91 (0.82-0.99)
REACH-	B .70	(0.59-	0.81) .66	(0.53-	0.80) .83	(0.75-	0.92)
FIB-	4 .79	(0.69-	0.89) .76	(0.65-	0.88) .86	(0.75-	0.98)
Log	APRI .69	(0.58-	0.80) .65	(0.53-	0.78) .81	(0.70-	0.91)
Invasive
PAGE-	B	+	Ishak .87 (0.82-0.93) .84 (0.78-0.91) .92 (0.85-0.99)
GAG-	HCCa .82	(0.75-	0.89) .78	(0.70-	0.87) .91	(0.86-	0.96)
CU-	HCCa .73	(0.63-	0.84) .69	(0.55-	0.82) .84	(0.73-	0.95)
Ishak	fibrosis .78	(0.70-	0.86) .75	(0.66-	0.84) .87	(0.81-	0.94)
aThe	GAG-	HCC	and	CU-	HCC	scores	already	 include	the	diagnosis	of	cirrhosis,	which	 in	the	current	
study	is	solely	based	on	liver	biopsy,	and	are	therefore	“invasive	markers”.
In	bold,	the	noninvasive	or	invasive	marker	with	the	highest	C-	statistic.
TABLE  3 C-	statistic	for	the	prediction	
of	clinical	outcome	by	prognostic	
biomarkers
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F IGURE  1 Kaplan-	Meier	curves	for	
(A)	event-	free	survival,	(B)	transplant-	free	
survival	and	hepatocellular	carcinoma	
(HCC),	(C)	free	follow-	up	according	to	
PAGE-	B	risk	score	<10,	10-	17	and	>17	
points
(A)
(B)
(C)
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of	Caucasian	CHB	patients	under	highly	potent	NA	therapy	only.17,18 
Because	 of	 the	 different	 composition	 of	 the	 cohort	 in	 the	 current	
study	in	terms	of	untreated	CHB	patients	and	those	of	different	ethnic	
origin	and	with	different	severity	of	liver	disease,	our	findings	further	
underline	the	robustness	and	generalizability	of	the	PAGE-	B	score	for	
the	use	in	clinical	practice.
F IGURE  2  (A)	Two-	year	to	20-	year	
risk	of	any	clinical	event	or	hepatocellular	
carcinoma	(HCC)	(B)	as	a	function	of	the	
PAGE-	B	score
(A)
(B)
TABLE  4 C-	statistic	for	the	prediction	of	any	clinical	event	within	different	subgroups
Biomarker 
C- statistic 
(95% CI) 
n (cases)/N 
(subgroup)
Within AVT 
after biopsy 
(n/N=27/348)
Within no  
AVT after 
biopsy 
(n/N=13/209)
Within 
Advanced 
fibrosis 
(n/N=22/113)
Within no 
advanced 
fibrosis  
(n/N=18/444)
Caucasian 
patients 
(n/N=27/261)
Asian patients  
(n/N=7/175)
African  
patients  
(n/N=5/104)
Noninvasive
PAGE-	B .83 (0.75-0.92) .91 (0.82-0.99) .81	(0.70-	0.93) .81 (0.72-0.91) .89 (0.82-0.96) .87 (0.75-0.99) .78 (0.58-0.98)
REACH-	B .73	(0.62-	0.85) .66	(0.46-	0.86) .65	(0.49-	0.82) .65	(0.46-	0.84) .71	(0.57-	0.85) .87 (0.77-0.98) .49	(0.23-	0.76)
FIB-	4 .79	(0.69-	0.88) .77	(0.53-	0.99) .82 (0.70-0.93) .65	(0.47-	0.83) .83	(0.73-	0.92) .81	(0.67-	0.96) .61	(0.24-	0.99)
Log	APRI .67	(0.56-	0.78) .68	(0.42-	0.98) .68	(0.55-	0.82) .50	(0.31-	0.68) .72	(0.62-	0.83) .77	(0.62-	0.91) .48	(0.10-	0.86)
Invasive
PAGE-	B	+	
Ishak
.85 (0.78-0.92) .90 (0.81-0.99) .82 (0.73-0.92) .79 (0.69-0.89) .88 (0.81-0.95) .94	(0.87-	0.99) .80 (0.62-0.98)
GAG-	HCCa .83	(0.76-	0.90) .82	(0.70-	0.94) .71	(0.58-	0.83) .74	(0.62-	0.86) .79	(0.70-	0.88) .97 (0.94-0.99) .68	(0.46-	0.91)
CU-	HCCa .78	(0.68-	0.88) .67	(0.46-	0.88) .77	(0.64-	0.90) .52	(0.36-	0.68) .68	(0.54-	0.82) .95	(0.90-	0.99) .61	(0.28-	0.94)
Ishak	fibrosis .77	(0.68-	0.87) .80	(0.67-	0.93) .72	(0.61-	0.83) .61	(0.49-	0.72) .73	(0.63-	0.84) .92	(0.85-	0.99) .75	(0.52-	0.98)
aThe	GAG-	HCC	and	CU-	HCC	scores	already	include	the	diagnosis	of	cirrhosis,	which	in	the	current	study	is	solely	based	on	liver	biopsy,	and	are	therefore	
“invasive	markers.”
AVT,	antiviral	therapy.
In	bold,	the	noninvasive	or	invasive	marker	with	the	highest	C-	statistic.
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For	decades,	the	gold	standard	to	assess	the	severity	of	liver	dis-
ease	 has	 been	 liver	 biopsy.7	With	 the	 combination	 of	 the	 PAGE-	B	
score	and	the	Ishak	stage,	the	long-	term	risk	prediction	improved	only	
minimally	(from	a	C-	statistic	of	.86	to	.87).	It	could	be	debated	whether	
the	slight	improvement	in	the	detection	of	events	justifies	a	liver	bi-
opsy	with	its	accompanying	risk	for	potentially	severe	complications,	
observer	and	sampling	limitations,	while	the	PAGE-	B	score	is	an	objec-
tive,	readily	available	and	relative	simple	risk	score.
A	strength	of	the	current	study	is	that	all	liver	biopsies	were	scored	by	
a	 single	experienced	hepato-	pathologist,	which	excludes	 interobserver	
and	also	minimizes	 intra-	observer	variation.23	Moreover,	 the	 long-	term	
follow-	up	data	were	both	obtained	from	the	municipal	record	database	as	
well	as	from	the	national	HCC	registry	database.	As	a	result,	data	on	HCC	
development	and	survival	were	complete	for	93%	of	the	cohort.	We	were	
not	able	 to	assess	 the	effect	of	AVT	on	outcome	because	of	different	
AVT	regimens,	different	response	criteria	and	significant	differences	be-
tween	patients	who	were	or	were	not	treated.	Although	this	is	an	import-
ant	question,	this	analysis	was	outside	the	scope	of	this	article,	and	more	
importantly,	we	have	shown	that	 the	PAGE-	B	score	had	the	best	pre-
dictive	ability	for	treated	or	untreated	patients	separately.	Furthermore,	
we	could	not	obtain	repeated	measurements	to	evaluate	the	longitudinal	
behaviour	of	the	risk	scores,	and	did	not	have	data	on	transient	elastogra-
phy	or	HBsAg	levels.	It	would	be	important	to	assess	the	added	value	of	
these	factors	to	the	PAGE-	B	score	in	future	research.28-31
In	 conclusion,	 we	 have	 shown	 that	 the	 PAGE-	B	 score	 was	 the	
best	performing	noninvasive	score	to	predict	the	clinical	outcome	of	
CHB	patients	of	different	origin	and	within	different	subgroups.	The	
Ishak	stage	did	not	clinically	improve	the	risk	prediction	of	the	PAGE-	B	
score.	When	further	validated,	this	score	could	additionally	be	used	to	
assess	the	need	for	AVT	and	HCC	surveillance.
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